Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Provibio Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are split between 2 distinct examiners and 2 distinct art units. This means that each of the 2 pending office actions is being reviewed in a different technical environment by a different examiner.
The busiest examiner for the company is SZNAIDMAN, MARCOS L, who is currently managing 1 pending action. With 2 distinct examiners and 2 distinct art units involved for only 2 pending office actions, the portfolio's current activity is decentralized. Practitioners must adapt to the specific standards of both distinct art units and the individual styles of the 2 distinct examiners to resolve these matters. Because there is no overlap between the 2 distinct examiners or the 2 distinct art units, each of the 2 pending office actions requires a completely independent prosecution strategy. Success with SZNAIDMAN, MARCOS L will not necessarily provide a roadmap for the other pending case, necessitating a versatile approach to these 2 distinct actions within the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| BURKETT, DANIEL JOHN | 1 | 62.6% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263059 | IMMUNOSUPPRESSIVE PHARMACEUTICAL COMPOSITION INCLUDING BENZENE DERIVATIVE AS IMMUNOSUPPRESSANT | BURKETT, DANIEL JOHN | 53d |
| 19548797 | PDK1 REGULATORY COMPOUND AND COMPOSITION CONTAINING THE SAME | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263059 | IMMUNOSUPPRESSIVE PHARMACEUTICAL COMPOSITION INCLUDING BENZENE DERIVATIVE AS IMMUNOSUPPRESSANT | BURKETT, DANIEL JOHN | 53d |
| 19548797 | PDK1 REGULATORY COMPOUND AND COMPOSITION CONTAINING THE SAME | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19548797 | PDK1 REGULATORY COMPOUND AND COMPOSITION CONTAINING THE SAME | SZNAIDMAN, MARCOS L | 1628 | §101§102§112DP | Non-Final OA | — | Pending | Feb 24, 2026 |
| 18263059 | IMMUNOSUPPRESSIVE PHARMACEUTICAL COMPOSITION INCLUDING BENZENE DERIVATIVE AS IMMUNOSUPPRESSANT | BURKETT, DANIEL JOHN | 1624 | §102§112 | Final Rejection | 53d | Pending | Jul 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial